NTRK1 and cancer: Finally, NTRK1-3 fusions are found with a low prevalence across different cancer types, including nonsquamous NSCLC [41], and are associated with the efficacy of tropomyosin receptor kinase (TRK) inhibitors (entrectinib and larotrectinib), which have received agnostic approval by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) [42,43].